



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/572,958-Conf. #7522	
			Filing Date	July 13, 2006	
			First Named Inventor	Dizhong Chen	
			Art Unit	2024	
			Examiner Name	Not Assigned STOCKTON	
Sheet	1	of	1	Attorney Docket Number	14090-00003-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-20050159470-A1	07-21-2005	Bressi et al.	
	AB*	US-2005-0137232-A1	06-23-2005	Bressi et al.	
	AC*	US-20050137234-A1	06-23-2005	Bressi et al.	
	AD*	US-20040266769-A1	12-30-2004	Bressi et al.	
	AE*	US-20040254220-A1	12-16-2004	Bressi et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-2006/101456-A1	09-28-2006	S*Bio Pte Ltd		
	BB	WO-02/42273-A2	05-30-2002	Bristol-Myers Squibb Company		
	BC	WO-00/34254-A1	06-15-2000	Astrazeneca AB		
	BD	WO-93/23041-A1	11-25-1993	Merck & Co Inc		
	BE	WO-02/10137-A2	02-07-2002	Signal Pharmaceuticals Inc		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	Witty et al., Tetrahedron Letters, Vol. 37, 1996, 3067-3070		
	CB	Gupta et al., Letters in Drug Design & Discovery, Vol. 2, 2005, 522-528		
	CD	Bare et al., Journal of Medicinal Chemistry, Vol. 32, 1989, 2561-2573		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/

Examiner Signature	/Laura L. Stockton/	Date Considered	12/16/2008
-----------------------	---------------------	--------------------	------------